Physician profile
Robert C O Laughlin
NPI 1699841254
$1,824.54
in general payments reported to CMS, 2019-2025
33 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $86.47 · 2021: $296 · 2022: $182 · 2023: $506 · 2024: $343 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $271.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.78 | 2023-2024 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $145.98 | 2019-2025 | |
| Janssen Biotech, INC. | $139.71 | 2019-2025 | Rybrevant, Imbruvica, Darzalex |
| Merck Sharp & Dohme LLC | $121.41 | 2021-2025 | Keytruda |
| Amgen INC. | $108.14 | 2019-2023 | Lumakras |
| Blue Earth Diagnostics | $101.94 | 2022-2024 | |
| Genzyme Corporation | $97.84 | 2021-2023 | |
| Aveo Pharmaceuticals, INC. | $83.01 | 2022-2024 | Fotivda |
| Emd Serono, INC. | $43.59 | 2024 | |
| Medtronic USA, INC. | $42.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $40.11 | 2020-2021 | |
| Stemline Therapeutics INC. | $39.68 | 2021-2024 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.68 | 2021-2025 | |
| Daiichi Sankyo INC. | $33.05 | 2021-2023 | Enhertu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $27.59 | 2021-2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $27.05 | 2020 | |
| Progenics Pharmaceuticals, INC. | $26.17 | 2023 | Pylarify |
| Telix Pharmaceuticals | $25.28 | 2024 | Illuccix |
| Incyte Corporation | $24.41 | 2025 | Monjuvi, Zynyz |
| Beigene USA, INC. | $23.00 | 2023 | Brukinsa |
| Adaptive Biotechnologies Corporation | $22.70 | 2025 | Clonoseq |
| Acrotech Biopharma INC. | $22.05 | 2021 | |
| Agios Pharmaceuticals, INC. | $21.36 | 2024 | Pyrukynd |
| Pfizer INC. | $20.45 | 2025 | |
| Dendreon Pharmaceuticals LLC | $20.12 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.35 | 2020 | |
| Morphosys, US INC. | $19.16 | 2023 | Monjuvi |
| Jazz Pharmaceuticals INC. | $17.19 | 2021 | |
| Novocure INC. | $14.51 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $14.10 | 2025 | |
| Eusa Pharma (US) LLC | $12.38 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert O Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.